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No improvement in long-term survival over time for
chronic lymphocytic leukemia patients in 
stereotyped subsets #1 and #2 treated with
chemo(immuno)therapy   
The overall survival of patients with chronic lympho-
cytic leukemia (CLL) has improved over the last decades
mainly due to advances in the understanding of the dis-
ease biology and the introduction of novel therapeutic
approaches.1 In this retrospective study we investigated
trends in overall survival in subgroups of cases defined by
genetic and immunogenetic features with the aim of
addressing the question whether advances in chemoim-
munotherapy had a uniform impact across all CLL
patients. We found that such advances have translated
into prolonged overall survival in all prognostic sub-
groups examined except those carrying TP53 abnormali-
ties, as expected, but also those assigned to stereotyped
subsets #1 and #2, which are generally devoid of such
gene aberrations. This latter finding, reported here for the
first time, indicates the need for alternative treatment
options for these patients.
A milestone in the management of CLL was the intro-
duction of combined chemoimmunotherapy, in particular
the fludarabine-cyclophosphamide-rituximab (FCR) regi-
men.2 FCR is the gold standard first-line treatment for
medically fit CLL patients except those carrying aberra-
tions of the TP53 gene (TP53abs: i.e. deletion of chromo-
some 17p, del(17p) and/or TP53 mutations) who should
be managed using signaling inhibitors.3 Additional
options, consisting of different combinations of
chemotherapeutic agents, anti-CD20 antibodies, signal-
ing inhibitors and the BCL2 inhibitor venetoclax hold
promise for further improvement of patients’ care.4
The remarkable efficacy of signaling inhibitors in CLL
can be considered as in vivo evidence of the critical role of
the B-cell receptor immunoglobulin in disease ontogeny
and evolution.5 This is further supported by the fact that
the somatic hypermutation status of the clonotypic
immunoglobulin heavy variable (IGHV) gene segregates
CLL cases into two categories with markedly different
outcomes: cases with no or limited somatic hypermuta-
tion load (germline identity ≥98%, “unmutated CLL”, U-
CLL), who generally have an aggressive disease course, in
contrast to cases with a germline identify <98% (“mutat-
ed CLL”, M-CLL) who usually have a more indolent dis-
ease.5 
Moreover, CLL patients can be assigned to specific sub-
groups, termed stereotyped subsets, each characterized
by a distinctive variable heavy complementarity deter-
mining region 3 (VH CDR3) within the B-cell receptor
immunoglobulin, which is shared between cases in each
stereotyped subset.6 The two largest stereotyped subsets
are subset #1 (clan I IGHV genes/IGKV1(D)-39, U-CLL),
representing 2.2-2.5% of all cases of CLL and 5% of U-
CLL, and subset #2 (IGHV3-21/IGLV3-21), the largest
overall, representing approximately 3% of all CLL and
comprising both U-CLL and mostly M-CLL.7 We have
previously reported that patients assigned to subsets #1
and #2 have a short time-to-first-treatment, similar to
that of patients harboring TP53abs, even though ~80%
and ~95% of subset #1 and #2 cases, respectively, lack
such aberrations.6,8
In the present study we explored survival trends based
on the date of primary treatment in a cohort of 3504
patients who had received at least one line of treatment
(Online Supplementary Tables S1 and S2), focusing on sub-
groups of patients with particular biomarker profiles
including those belonging to stereotyped subsets #1 and
#2. The present series was consolidated within the con-
text of a multicenter collaboration of 15 institutions from
nine countries in Europe and the USA. The clinicobiolog-
ical data were retrieved from the local registry of each
institution. Information regarding gender, age at the time
of primary treatment, as well as immunogenetic features
was available for all patients, while fluorescence in situ
hybridization data were available for 1857 (53%)
patients. Details regarding the molecular analyses are
provided in the Online Supplementary Material. The study
was approved by the local ethics review committee in
each participating center.
The evaluated  patients received primary treatment
between May 1980 and February 2014 and were strati-
fied into two groups based on the date of this treatment;
group A (n=2093) received primary treatment before
2006 and group B (n=1411) received primary treatment
after January 1, 2006 (Table 1). The cut-off dates of
January 2006 and February 2014 were chosen as they
mark, respectively, the introduction of chemoim-
haematologica 2018; 103:e158
LETTERS TO THE EDITOR
Table 1. Main clinicobiological features of cases treated before and after 2006.
Treated 1980-2005 Treated 2006-2014 P
n=2093 n=1411
Male 1443/2093, 69% 968/1411, 69% 0.83
Median age at treatmenta(years, range) 63 (22-92) 64.4 (33-92) 0.001
M-CLL 768/2093, 37% 518/1411, 37% 0.99
del(13q)* 323/570, 57% 205/383, 54% 0.33
Trisomy 12* 133/706, 19% 106/495, 21% 0.27
del(11q)* 199/937, 21% 140/676, 21% 0.79
del(17p)* 111/1059, 10% 106/798, 13% 0.063
Subset #2b 105/2093, 5% 61/1411, 4% 0.34
Subset #1c 68/2093, 3.2% 42/1411, 3% 0.65
Median overall survival 9.5 years 17.5 years <0.0001
aDespite the fact that the two groups have a similar median age, the identified 1.4-year difference emerged as statistically significant due to the variation within groups as
well as the large number of cases included in each group. *According to the Döhner hierarchical model, bAssignment to stereotyped subset #2, cAssignment to stereotyped
subset #1.
munotherapy into clinical practice9 and, the date of the
USA Food and Drug Administration approval for the use
of ibrutinib in CLL.
Associations regarding categorical variables were
assessed using the c2 test. Overall survival was measured
from the date of diagnosis until the date of last follow-up
or death, in order to minimize potential bias due to the
longer follow up of the patients treated before 2006.
Survival curves were constructed with the Kaplan-Meier
method, and the log-rank test was used to determine sta-
tistically significant differences between survival propor-
tions. All tests were two-sided and statistical significance
was defined as a P-value <0.05. Statistical analysis was
performed using the Statistica Software v.10·0
(StatSoftInc, Tulsa, OK, USA).
Group A (1980-2005) and group B (2006-2014) had
similar basic demographics, immunogenetic features and
cytogenetic profiles (Table 1). However, the overall sur-
vival of group A was significantly (P<0.0001) inferior
compared to that of group B [median overall survival: 9.5
years (95% confidence interval [CI]: 0.1-17.1) versus 17.5
years (CI: 0.1-17.9) in groups A and B respectively,
P<0.0001] (Figure 1A). This superior outcome of group B
patients was evident across subgroups defined by age,
gender, somatic hypermutation status, del(11q), trisomy
12 and del(13q) (P<0.05 for all comparisons to the corre-
sponding group A subgroups) (Figure 1, Online
Supplementary Figures S1 and S2).
In contrast, no increase in overall survival was seen
over time for cases with del(17p) [median overall sur-
vival: 7.7 years (95% CI: 0.1-18.1) versus 5.2 years (95%
CI: 0.1-10.1) in groups A and B respectively, P=0.61]
(Figure 1C), which is not unexpected given the docu-
mented low efficacy of chemo(immuno)therapy in
patients with TP53abs.2 Notably, a similar lack of
improvement in overall survival was observed for cases
assigned to subset #1 [median overall survival: 6.6 years
(95% CI: 0.1-8.5) versus 8.3 years (95% CI: 0.1-15.1) in
groups A and B respectively, P=0.31] and subset #2
[median overall survival: 7.3 years (95% CI: 0.1-10.3) 
versus 10.7 years (95% CI: 0.1-16.4) in groups A and B
respectively, P=0.14] (Figure 1D,E). Survival differences
between groups A and B remained non-significant for
subsets #1 and #2, even when cases positive for del(17p)
were excluded from the analysis (P=0.94 and P=0.95,
respectively) (Figure 1F, Online Supplementary Figure S3).
TP53abs represent the only predictive biomarker
affecting the treatment choice in CLL,3 but not all
chemorefractory cases carry TP53abs. Instead, emerging
evidence highlights other genomic aberrations that may
complete the puzzle of chemorefractoriness.10 The pres-
ent study goes beyond genomic aberrations, highlighting
a notable lack of improvement in overall survival over the
last 35 years for patients belonging to stereotyped sub-
sets #1 and #2, despite the refinement of
chemo(immuno)therapy regimens. Admittedly, despite
this evidence, caution is warranted since, due to the ret-
rospective nature of our study, the evaluated patients had
received different therapeutic regimens rather than a uni-
form treatment, thus necessitating further investigation
before definitive conclusions can be drawn.
Obviously,  it would be reasonable to ask whether the
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Figure 1. Overall survival for patients with chronic lymphocytic leukemia in the present cohort. (A) Inferior overall survival (OS) for cases treated between 1980-
2005 (blue line) versus cases treated between 2006-2014 (red line). (B) Inferior OS for all U-CLL cases treated between 1980-2005. (C-E) No improvement in
OS over time for patients carrying del(17p) (C) or patients belonging to subset #1 (D) or subset #2 (E). (F) No improvement in OS over time for cases belonging
to subset #2 even after excluding del(17p) cases. 
A B C 
D E F
genomic landscape of these subsets per se might explain
their noted clinical aggressiveness. This question could
not be addressed systematically in the present study due
to missing information, especially concerning recurrent
gene mutations. Nonetheless, based on the literature,
subset #1 exhibits a rather diverse genomic landscape,8
hence rendering it difficult to draw definitive conclusions
regarding the potential impact of each single individual
abnormality. In contrast, subset #2 frequently shows
del(13q) and  del(11q) (in up to 54% and 24% cases,
respectively), as well as enrichment for SF3B1 and ATM
mutations (frequency ~45% and 26%, respectively),
which might reasonably be considered as contributing to
the clinical aggressiveness of mutant cases.8,11 Notably,
however, subset #2 cases lacking SF3B1 mutations have
an equally aggressive clinical course as mutant cases,
implying that the dismal outcome of subset #2 is more
closely linked to its unique clonotypic antigen receptor
rather than a particular genomic aberration.8 In line with
this, del(13q) or del(11q) did not have an impact on over-
all survival within subset #2 cases of our study (Online
Supplementary Figure S4). 
Recent studies support that patients with M-CLL treat-
ed with FCR achieve long-lasting responses, often with
no detectable minimal residual disease, thus in contrast
with U-CLL cases,12-14 prompting consideration of
whether somatic hypermutation status should be used
for making treatment decisions in medically fit patients
with CLL. Along this line, our study implies that other
immunogenetic features in addition to, but also beyond,
somatic hypermutation status i.e. B-cell receptor
immunoglobulin stereotypy, may predict inferior
responses to chemo(immuno)therapy, regardless of
genomic aberrations, further highlighting the significance
of comprehensive immunogenetic analysis in CLL.15
Consequently, it could be argued that alternative options
should be considered for subset #1 and #2 patients in the
context of prospective trials. However, given the inherent
limitations of retrospective analysis, subgroup analyses
based on prospective clinical studies with targeted agents
are warranted to further inform such a change in treat-
ment regimens for these subsets. 
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